DK486588A - CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES - Google Patents
CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINESInfo
- Publication number
- DK486588A DK486588A DK486588A DK486588A DK486588A DK 486588 A DK486588 A DK 486588A DK 486588 A DK486588 A DK 486588A DK 486588 A DK486588 A DK 486588A DK 486588 A DK486588 A DK 486588A
- Authority
- DK
- Denmark
- Prior art keywords
- immunglobulines
- cytoqinines
- conjunates
- conjugates
- cytokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G99/00—Subject matter not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The conjugates consist of a cytokine, for example interferon alpha, and human immunoglobulin, if required linked via an organic bridge and are used in pharmaceutical preparations for the treatment of viral infections and tumours. Compared with the free cytokine, the conjugates have a longer residence time in the plasma and tissue and thus improve the therapeutic effect.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH335787 | 1987-09-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK486588D0 DK486588D0 (en) | 1988-09-01 |
DK486588A true DK486588A (en) | 1989-03-03 |
Family
ID=4254228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK486588A DK486588A (en) | 1987-09-02 | 1988-09-01 | CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0305967B1 (en) |
JP (1) | JPS6490200A (en) |
KR (1) | KR890005137A (en) |
AT (1) | ATE88900T1 (en) |
AU (1) | AU627694B2 (en) |
DE (1) | DE3880766D1 (en) |
DK (1) | DK486588A (en) |
ES (1) | ES2054753T3 (en) |
FI (1) | FI884013A (en) |
IL (1) | IL87621A0 (en) |
NO (1) | NO883896L (en) |
NZ (1) | NZ226005A (en) |
PH (1) | PH26813A (en) |
PT (1) | PT88385B (en) |
ZA (1) | ZA886471B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3818055A1 (en) * | 1988-05-27 | 1989-11-30 | Biotest Pharma Gmbh | COMBINATION OF HUMAN IMMUNOGLOBULINS AND INTERLEUKIN-2 FOR THE TREATMENT OF INFECTION DISEASES |
GB8820378D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
GB8820377D0 (en) * | 1988-08-26 | 1988-09-28 | Offord R E | Chemical compounds |
KR900005995A (en) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
DE3839332A1 (en) * | 1988-11-22 | 1990-05-23 | Bayer Ag | METHOD FOR PRODUCING SUBSTITUTED 2-CHLORINE PYRIDINES |
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5478804A (en) * | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
EP0565620B1 (en) * | 1991-01-03 | 1995-09-20 | The Salk Institute For Biological Studies | Mitotoxin for treatment of vascular injury |
EP0660723B1 (en) * | 1991-02-04 | 1996-08-21 | The University of Saskatchewan | Vp6 encapsulated drug delivery |
PT100090A (en) * | 1991-02-04 | 1993-07-30 | Univ Saskatchewan | Method for targeting and release of drugs |
JP3105629B2 (en) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | Cell activity regulating conjugates of members of specific binding pairs |
EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US7754211B2 (en) | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
JPH10511989A (en) * | 1996-04-10 | 1998-11-17 | サングスタット メディカル コーポレイション | Cell regulatory complex of specific binding pair members |
IT1289608B1 (en) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL |
CA2693296C (en) | 1997-12-08 | 2013-09-10 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ATE316982T1 (en) | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | MULTIPLE CYTOKINE ANTIBODIES COMPLEXES |
ATE336514T1 (en) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | INCREASE THE CIRCULATION HALF-LIFE OF ANTIBODIES-BASED FUSION PROTEINS |
MXPA02009454A (en) | 2000-03-31 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand immunogen conjugates. |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
JP4309662B2 (en) | 2001-05-03 | 2009-08-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tumor-specific recombinant antibodies and uses thereof |
JP2004535202A (en) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | Therapeutic agents containing pro-apoptotic proteins |
EP2354791A1 (en) | 2001-12-04 | 2011-08-10 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
BRPI0418286A (en) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | il-7 fusion proteins |
JP4987484B2 (en) | 2004-01-22 | 2012-07-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anticancer antibodies with reduced complement binding |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
DK1966245T3 (en) | 2005-12-30 | 2011-07-18 | Merck Patent Gmbh | Anti-CD19 Antibodies with Reduced Immunogenicity |
CN101351475B (en) | 2005-12-30 | 2013-05-15 | 默克专利有限公司 | Interleukin-12p40 variants with improved stability |
CN102405230A (en) | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | Antibody fusion proteins with modified fcrn binding sites |
JP5879713B2 (en) * | 2010-12-09 | 2016-03-08 | ソニー株式会社 | Image processing apparatus, image processing method, and program |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
CA2909576C (en) | 2013-04-19 | 2023-07-18 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1564666A (en) * | 1978-05-31 | 1980-04-10 | Ng Mun Hon | Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof |
-
1988
- 1988-08-30 EP EP88114130A patent/EP0305967B1/en not_active Expired - Lifetime
- 1988-08-30 DE DE8888114130T patent/DE3880766D1/en not_active Expired - Fee Related
- 1988-08-30 PH PH37474A patent/PH26813A/en unknown
- 1988-08-30 ES ES88114130T patent/ES2054753T3/en not_active Expired - Lifetime
- 1988-08-30 AT AT88114130T patent/ATE88900T1/en not_active IP Right Cessation
- 1988-08-31 PT PT88385A patent/PT88385B/en not_active IP Right Cessation
- 1988-08-31 NZ NZ226005A patent/NZ226005A/en unknown
- 1988-08-31 ZA ZA886471A patent/ZA886471B/en unknown
- 1988-08-31 IL IL87621A patent/IL87621A0/en unknown
- 1988-08-31 FI FI884013A patent/FI884013A/en not_active IP Right Cessation
- 1988-09-01 NO NO88883896A patent/NO883896L/en unknown
- 1988-09-01 KR KR1019880011274A patent/KR890005137A/en not_active Application Discontinuation
- 1988-09-01 AU AU21725/88A patent/AU627694B2/en not_active Ceased
- 1988-09-01 JP JP63216441A patent/JPS6490200A/en active Pending
- 1988-09-01 DK DK486588A patent/DK486588A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ226005A (en) | 1990-10-26 |
PH26813A (en) | 1992-11-05 |
KR890005137A (en) | 1989-05-13 |
EP0305967B1 (en) | 1993-05-05 |
EP0305967A2 (en) | 1989-03-08 |
NO883896L (en) | 1989-03-03 |
DK486588D0 (en) | 1988-09-01 |
PT88385A (en) | 1989-07-31 |
DE3880766D1 (en) | 1993-06-09 |
JPS6490200A (en) | 1989-04-06 |
ATE88900T1 (en) | 1993-05-15 |
NO883896D0 (en) | 1988-09-01 |
ZA886471B (en) | 1989-04-26 |
EP0305967A3 (en) | 1990-01-31 |
AU2172588A (en) | 1989-03-23 |
FI884013A0 (en) | 1988-08-31 |
IL87621A0 (en) | 1989-01-31 |
AU627694B2 (en) | 1992-09-03 |
ES2054753T3 (en) | 1994-08-16 |
FI884013A (en) | 1989-03-03 |
PT88385B (en) | 1992-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK486588D0 (en) | CONJUNATES OF CYTOQININES WITH IMMUNGLOBULINES | |
DK184186D0 (en) | THERAPEUTIC PREPARATION FOR TREATMENT OF VIRUSAL DISEASES | |
DK0911033T4 (en) | Use of consensus interferon to reduce the side effects of interferon therapy in viral hepatitis | |
GEP19981482B (en) | Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B | |
ATE72991T1 (en) | NASAL ADMINISTRATION OF MEDICATIONS. | |
FI862011A (en) | THERAPEUTIC NUCLEOSIDER. | |
DE68929551D1 (en) | Human DNase | |
DK602988D0 (en) | NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL EFFECT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS | |
DE59101397D1 (en) | O-GLYCOSYLATED IFN ALPHA. | |
DE69130071D1 (en) | COMPOSITION USED AS A THERAPEUTIC AGENT AGAINST CHRONIC VIRAL LIVER DISEASES | |
NO931413D0 (en) | METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES | |
DE68912155D1 (en) | Combination antiviral. | |
DK68388D0 (en) | APPLICATION OF OXOCHINAZOLINE DERIVATIVES FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT HYPERURIC AEMIA | |
ES2037807T3 (en) | MEDICINES CONTAINING IN INTERFERON COMBINATION AND 1-DEOXY-PIPERIDINES, PROCEDURE FOR THEIR MANUFACTURE AND APPLICATION. | |
EA199800770A1 (en) | DRUGS FOR THERAPEUTIC TREATMENT OF VIRAL HEPATITIS | |
ES2103811T3 (en) | ANTIVIRAL THERAPY. | |
ATE92333T1 (en) | MEDICATIONS FOR THE INTRALESION TREATMENT OF SCALP-LIKE CELL CARCINOMA WITH RECOMBINANT HUMAN ALPHA INTERFERON. | |
DK0579765T3 (en) | Method and Preparation for the Treatment of Herpes-Related Diseases | |
DK0427633T3 (en) | Use of a polypeptide with gamma interferon activity for the preparation of pharmaceutical preparations intended for the treatment of primitive pleural cancer | |
ES2038578T1 (en) | USE OF HUMAN G IMMUNOGLOBULINS, OR OF THESE FC FRAGMENTS, AS A PREPARATORY MEDICINE FOR THE ADMINISTRATION OF MONOCLONAL ANTIBODIES TO MEN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHB | Application shelved due to non-payment | ||
AHB | Application shelved due to non-payment |